A Deep Dive into Hormonal Health and Treatment Options

A Deep Dive into Hormonal Health, Metabolism, and Integrative Care

Abstract

In this educational post, I will take you on a journey through the complex world of hormonal health, drawing upon the latest evidence-based research and my clinical experience. We will explore the nuanced management of common conditions like iron deficiency anemia and Polycystic Ovary Syndrome (PCOS), and the challenges of hormone replacement therapy in unique patient populations, such as those who have undergone gastric bypass surgery. I will dive into the physiological principles of hormone absorption, distribution, and excretion, explaining how factors like age, body composition, and kidney function influence treatment outcomes. We will also dissect the complex relationship between testosterone, sex hormone-binding globulin (SHBG), and effective treatment strategies for all individuals. Furthermore, I will address critical safety considerations, such as the risk of deep vein thrombosis (DVT) with contraceptive use in different age groups, and debunk common myths surrounding testosterone therapy. A key focus will be on the integrative chiropractic approach, which complements these biomedical strategies by addressing the body’s foundational structure and function, enhancing overall physiological resilience and optimizing patient outcomes.

Navigating Heavy Menstrual Bleeding and Iron Deficiency

One of the most frequent issues I see in my female patients is heavy menstrual bleeding, which almost invariably leads to iron deficiency. It’s a pervasive problem that can significantly impact a woman’s quality of life, causing fatigue, brain fog, and a general decline in well-being. When a patient presents with these symptoms, my initial step is always to get the right team involved and to think systematically.

The first line of defense is often to address the iron deficiency directly. However, simply supplementing with iron isn’t enough; we need to understand the underlying mechanisms. For instance, copper status is critical for proper iron metabolism. Without adequate copper, iron can get “stuck” and is not properly utilized to form hemoglobin, leading to anemia even with sufficient iron intake. This is why a comprehensive nutritional assessment is paramount.

For the heavy bleeding itself, hormonal modulation is a powerful tool.

• Cyclic Progesterone: I often utilize cyclic progesterone to help regulate the menstrual cycle and reduce bleeding. For particularly heavy bleeding, I might start with a higher dose, such as 200mg nightly, for a set period (e.g., days 14-28 of the cycle). The goal is to establish a more controlled withdrawal bleed. However, continuous high-dose progesterone can eventually lead to breakthrough bleeding because the uterine lining doesn’t receive a clear signal to shed. A more sustainable approach for many is a lower dose, like 100mg nightly, which still helps manage fluctuations. I typically monitor the patient for about three months to see how their body responds before making further adjustments.
• Thyroid Function: It’s also crucial not to overlook the thyroid. Hypothyroidism is a common and often undiagnosed cause of heavy menstrual bleeding. Normalizing thyroid function is a key part of the protocol and can dramatically improve bleeding patterns, working synergistically with iron supplementation and progesterone therapy.

In my practice, I have observed that a multifaceted approach is the most effective. We can’t just treat the symptom (anemia); we must address the root causes (hormonal imbalance, nutritional deficiencies, and thyroid dysfunction).

Hormonal Considerations in Special Populations

PCOS and Bariatric Surgery Patients

Patients with Polycystic Ovary Syndrome (PCOS) and those who have undergone post-gastric bypass surgery present unique challenges and require a tailored approach to hormone management.

For my PCOS patients, hormonal imbalances, particularly elevated androgens and insulin resistance, are the central issue. The strategies discussed above, such as cycle regulation with progesterone and optimizing metabolic health, are foundational.

For patients after bariatric surgery, the primary concern is malabsorption. These individuals have a surgically altered digestive tract, which significantly impairs their ability to absorb nutrients and oral medications. When I treat these patients, whether for hormone balance or other issues, I maintain the same core principles of gut health support—using high-quality, broad-spectrum probiotics and targeted nutrients—but with a heightened awareness of absorption. Probiotics are essential here, as they help re-establish a healthy microbiome in the lower bowel, which is critical for the limited absorption capacity that remains. If oral supplements and medications are not being absorbed effectively, as evidenced by lab work and clinical symptoms, we must pivot to alternative delivery methods, such as transdermal or injectable therapies.

The Role of Integrative Chiropractic Care in Metabolism

This is where integrative chiropractic care becomes a vital component of the treatment plan. The nervous system is the master controller of all bodily functions, including digestion, metabolism, and endocrine (hormone) function. Spinal misalignments, or vertebral subluxations, can interfere with the nerve signals traveling between the brain and the digestive organs, including the stomach and intestines.

For a post-bariatric patient with an already compromised digestive system, ensuring optimal nerve function is non-negotiable. Through specific chiropractic adjustments, we can help restore proper neurological communication. This can improve gut motility, enhance the function of the remaining digestive tract, and support the body’s overall ability to regulate its internal environment (homeostasis). By improving the foundational function of the nervous system, we create a more resilient physiological state, making all other biomedical interventions, from probiotics to hormone therapy, more effective.

The Physiology of Hormone Replacement Therapy: Absorption, Distribution, and Excretion

When discussing hormone replacement, especially with subcutaneous pellets, it’s essential to understand the underlying physiology. A patient’s response to a given dose is not static; it’s a dynamic process governed by three key factors: absorption, distribution, and excretion.

1. Absorption: With hormone pellets, which are placed under the skin, absorption is primarily dependent on the surface area of the pellet and cardiac output. The tissue under the skin is rich with capillaries. The more blood that flows past the pellet, the faster the hormone is absorbed into the bloodstream. This is why I tell my patients that regular exercise is one of the best things they can do to optimize their therapy. Increased physical activity boosts cardiac output, leading to better, more consistent hormone levels.
2. Distribution: Once in the bloodstream, the hormone is distributed throughout the body. The volume of this distribution is largely determined by a person’s body mass and composition. A larger individual with more body fat has a larger “depot” for the hormone to spread out in. When a patient loses a significant amount of weight—for example, going from 250 pounds to 190 pounds after bariatric surgery—the volume of distribution shrinks. The same dose of testosterone now has less tissue to spread over, which can lead to higher effective concentrations. This is why we must re-evaluate and often lower the dose after significant weight loss.
3. Excretion: Finally, hormones are broken down and removed from the body. Testosterone, for instance, is almost entirely cleared by the kidneys (renal excretion). An individual’s kidney function, therefore, directly impacts how long the hormone lasts in their system. Older patients, particularly men in their 80s, often have naturally more sluggish kidney function. They excrete the hormone much more slowly. In my clinical experience, these are the patients who can go for six, or even up to nine, months on a single pellet insertion because the hormone simply lasts longer in their bodies. We must dose these patients much more conservatively to avoid excessive accumulation.

Understanding this “ADE” model is crucial for personalizing therapy and achieving optimal, safe outcomes for every patient.

Debunking Myths and Navigating Complex Cases

Testosterone, Estrogen, and Aromatase Inhibitors

A common question from male patients starting testosterone therapy revolves around symptoms of elevated estrogen, such as breast tenderness or sensitivity. This occurs when testosterone is converted into estrogen via the aromatase enzyme. Some practitioners might immediately reach for an aromatase inhibitor (AI) like anastrozole, but I urge caution.

In my experience, this “aromatization” tenderness is most common and pronounced only during the very first treatment cycle, when the body is adapting to a significant shift from very low to normal testosterone levels. After this initial phase, the body typically adjusts, and the symptom resolves on its own. I rarely, if ever, need to use medications like Diindolylmethane (DIM) or AIs for this long-term. If a patient who has been stable on therapy for a while suddenly complains of these symptoms, I am often skeptical. It may be an attempt to get a higher dose, based on “gym talk,” which can lead to adverse effects like poor erectile function. My approach is to educate the patient and manage their expectations from the start.

Contraception, SHBG, and DVT Risk

A particularly complex scenario involves women in their 40s who are on oral contraceptives. A 45-year-old woman recently came to me wanting to start testosterone therapy, but she was also taking birth control pills. This raises several red flags.

• DVT Risk: For a 20-year-old, the risk of a deep vein thrombosis (DVT) or stroke from oral contraceptives is relatively low, and the benefit of preventing pregnancy often outweighs this risk. For a 45-year-old, however, the baseline risk of a cardiovascular event is already higher. Adding oral estrogen from birth control pills significantly amplifies this risk, and the risk-benefit ratio is no longer favorable, especially if she doesn’t need it for contraception (e.g., has had a tubal ligation or uses an IUD).
• SHBG Elevation: Oral estrogens dramatically increase the production of Sex Hormone-Binding Globulin (SHBG) in the liver. SHBG is a protein that binds tightly to testosterone, rendering it inactive. A woman on birth control might have an SHBG level of 150 or higher. This means that even if we give her testosterone, it will be immediately “sponged up” by SHBG, and her free, biologically active testosterone will remain extremely low. She won’t feel any of the benefits until her total testosterone is pushed to very high levels (e.g., over 350-500 ng/dL), a territory where most practitioners are hesitant to go. These patients are notoriously difficult to treat and often remain dissatisfied.

My first step in this situation is to have a frank discussion about contraception. I strongly recommend discontinuing the oral contraceptive and switching to a non-estrogenic method, like a progestin-only IUD (Mirena, Liletta) or the copper IUD. This removes the exogenous estrogen load, which lowers her DVT risk and, critically, allows her SHBG level to decrease. Once SHBG normalizes, her body can effectively utilize testosterone, and she can achieve symptomatic relief at a much safer and lower dose.

Testosterone and Atrial Fibrillation (AFib)

I am often asked about the safety of testosterone therapy in patients with a history of cardiac issues, such as Atrial Fibrillation (AFib). There is a persistent myth that testosterone is risky in this context. The evidence points in the opposite direction.

Landmark research, including studies that appear first in a medical literature search, demonstrates that normalizing testosterone levels in men with androgen deficiency before a cardiac event or procedure, such as cardioversion, improves the likelihood of a successful outcome (Vikan, Schirmer, Njølstad, & Svartberg, 2009). AFib is an issue of an abnormal electrical pathway in the heart; it has absolutely no physiological connection to testosterone levels. There is no evidence linking testosterone replacement therapy to an increased risk of AFib. In fact, optimizing hormonal status supports overall cardiovascular health.

The Importance of Evidence-Based Practice and Continuous Learning

As a practitioner with multiple certifications, including the Institute for Functional Medicine (IFMCP), I am committed to a model of care deeply rooted in modern, evidence-based research. The field of medicine is not static; it is constantly evolving. What we believed to be true ten years ago may be refined or even replaced by new data today.

For example, our understanding of hormone therapy and breast cancer risk has become much more nuanced. Early studies (like the Women’s Health Initiative) that painted all hormones with a broad, negative brush are now understood to have been flawed. Newer, more precise research is distinguishing between different types of hormones (synthetic progestins vs. bioidentical progesterone) and their effects. It’s now becoming clear that the types and amounts of hormones used are critical factors, and some regimens may not carry the same risks as previously assumed (Holtorf, 2009).

This dedication to excellence is why I prioritize continuous education, both for myself and for my peers. By rigorously analyzing new literature and integrating the latest findings, we can provide the safest, most effective, and most personalized care to our patients. This journey is about pursuing excellence in everything we do, from the way we diagnose to the way we treat, ensuring that every patient benefits from the forefront of medical science.

---

References

• Holtorf, K. (2009). The bioidentical hormone debate: Are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Postgraduate Medicine, 121(1), 73–85. https://doi.org/10.3810/pgm.2009.01.1949
• Vikan, T., Schirmer, H., Njølstad, I., & Svartberg, J. (2009). Endogenous testosterone and the risk of atrial fibrillation in men: The Tromsø study. European Journal of Endocrinology, 161(4), 541–546. https://doi.org/10.1530/EJE-09-0217